In this video interview, David Morton, PhD, director of biostatistics at Certara, reflects on the growing role of Bayesian ...

As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more flexible, data-driven approaches that integrate prior knowledge, reduce sample ...

Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL ...

The primary goal of the trial was to optimize radiation therapy (RT) dose among three levels (low, standard, and high), given either with placebo (P) or an investigational agent (A), for treating ...

In July, when the FDA approved Eisai and Biogen’s Alzheimer’s drug Leqembi, we noted the historic nature of the news: it’s the first approved Alzheimer's treatment clinically shown to slow disease ...